ホーム › びまん性大細胞型B細胞リンパ腫 › ノースカロライナ
ノースカロライナにおけるびまん性大細胞型B細胞リンパ腫の臨床試験
ノースカロライナ内の拠点で、びまん性大細胞型B細胞リンパ腫に関する20件の研究が参加者を募集しています。
ノースカロライナ内の都市
公式研究テキスト（英語）
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- University of North Carolina Medical Center ( Site 0136), Chapel Hill
- Novant Health Presbyterian Medical Center ( Site 0177), Charlotte
- Novant Health Forsyth Medical Center ( Site 0206), Winston-Salem
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06890884A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Duke University Medical Center, Durham
- East Carolina University, Greenville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06091865A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- East Carolina University ( Site 0159), Greenville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06717347Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Novant Health Cancer Institute- Hematology, Charlotte
- Duke Blood Cancer Center, Durham
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/31更新 · NCT06500273A Study of ARC-02 in B-cell NHL
- Levine Cancer Institute, Charlotte
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/26更新 · NCT07691606Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Atrium Health Wake Forest Baptist, Winston-Salem
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/05更新 · NCT06116110A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Wake Forest University Health Sciences, Winston-Salem
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/09更新 · NCT06015880A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Duke University Medical Center, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/02更新 · NCT05131022Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- 他4件
被験者募集中観察研究
65歳以上 · 全性別 · 2026/06/29更新 · NCT01137825Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Duke Univerisity, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT04775745Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Cabarrus/LCI-Concord, Concord
- Wake Forest University Health Sciences, Winston-Salem
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/02更新 · NCT05633615Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
被験者募集中観察研究
18歳〜120歳 · 全性別 · 2025/10/27更新 · NCT01137643A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of North Carolina, Chapel Hill
被験者募集中第1相
18歳以上 · 全性別 · 2025/10/02更新 · NCT05780034A Study of NX-1607 in Adults With Advanced Malignancies
- University of North Carolina, Chapel Hill
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/09更新 · NCT05107674Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
被験者募集中第2相
18歳以上 · 全性別 · 2024/09/26更新 · NCT06238648DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Brody School of Medicine at East Carolina University, Greenville
被験者募集中第2相
18歳以上 · 全性別 · 2023/04/07更新 · NCT04920617ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。